Literature DB >> 23103823

A model to determine absolute risk for esophageal adenocarcinoma.

Aaron P Thrift1, Bradley J Kendall, Nirmala Pandeya, David C Whiteman.   

Abstract

BACKGROUND & AIMS: Esophageal adenocarcinoma (EAC) develops rapidly and has a high mortality rate. We aimed to develop a prediction model to estimate the absolute 5-year risks, based on different profiles of factors, for developing EAC.
METHODS: We derived a risk model using epidemiologic data from 364 patients with incident EAC and 1580 population controls. Significant risk factors were fitted into an unconditional multiple logistic regression model. The final model was combined with age- and sex-specific EAC incidence data to estimate absolute 5-year risks for EAC. We performed a 10-fold cross-validation of the data to assess the relative performance of the model.
RESULTS: The final risk model included terms for highest level of education, body mass index, smoking status, frequency of gastroesophageal reflux symptoms and/or use of acid-suppressant medications, and frequency of nonsteroidal anti-inflammatory drug use. The population attributable risk for the model was 0.92. A 10-fold cross-validation produced an area under the receiver operating characteristic curve statistic of 0.75 (95% confidence interval, 0.66-0.84), indicating good discrimination. Adding data on alarm symptoms, frequency of symptoms of dysphagia, and unexplained weight loss to the model significantly improved discrimination (area under the receiver operating characteristic curve, 0.85; 95% confidence interval, 0.78-0.91).
CONCLUSIONS: Risk models can be used to identify people with a higher than average risk for developing EAC; these individuals might benefit from targeted cancer-prevention strategies.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23103823     DOI: 10.1016/j.cgh.2012.10.026

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  23 in total

1.  Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma.

Authors:  Matthew F Buas; Haiwei Gu; Danijel Djukovic; Jiangjiang Zhu; Lynn Onstad; Brian J Reid; Daniel Raftery; Thomas L Vaughan
Journal:  Metabolomics       Date:  2017-01-20       Impact factor: 4.290

2.  Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm.

Authors:  Xiangqing Sun; Robert C Elston; Jill S Barnholtz-Sloan; Gary W Falk; William M Grady; Ashley Faulx; Sumeet K Mittal; Marcia Canto; Nicholas J Shaheen; Jean S Wang; Prasad G Iyer; Julian A Abrams; Ye D Tian; Joseph E Willis; Kishore Guda; Sanford D Markowitz; Apoorva Chandar; James M Warfe; Wendy Brock; Amitabh Chak
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02-29       Impact factor: 4.254

3.  Editorial: Best Practices in Surveillance of Barrett's Esophagus.

Authors:  Sachin Wani; Srinivas Gaddam
Journal:  Am J Gastroenterol       Date:  2017-07       Impact factor: 10.864

4.  Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus.

Authors:  Xiaohong Li; Thomas G Paulson; Patricia C Galipeau; Carissa A Sanchez; Karen Liu; Mary K Kuhner; Carlo C Maley; Steven G Self; Thomas L Vaughan; Brian J Reid; Patricia L Blount
Journal:  Cancer Prev Res (Phila)       Date:  2015-06-30

Review 5.  Barrett's Esophagus and Esophageal Adenocarcinoma: How Common Are They Really?

Authors:  Aaron P Thrift
Journal:  Dig Dis Sci       Date:  2018-08       Impact factor: 3.199

Review 6.  Global burden and epidemiology of Barrett oesophagus and oesophageal cancer.

Authors:  Aaron P Thrift
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-18       Impact factor: 46.802

7.  Risk Prediction Models for Head and Neck Cancer in the US Population From the INHANCE Consortium.

Authors:  Yuan-Chin Amy Lee; Mohammed Al-Temimi; Jian Ying; Joshua Muscat; Andrew F Olshan; Jose P Zevallos; Deborah M Winn; Guojun Li; Erich M Sturgis; Hal Morgenstern; Zuo-Feng Zhang; Elaine Smith; Karl Kelsey; Michael McClean; Thomas L Vaughan; Philip Lazarus; Chu Chen; Stephen M Schwartz; Maura Gillison; Stimson Schantz; Guo-Pei Yu; Gypsyamber D'Souza; Neil Gross; Marcus Monroe; Jaewhan Kim; Paolo Boffetta; Mia Hashibe
Journal:  Am J Epidemiol       Date:  2020-04-02       Impact factor: 4.897

Review 8.  Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions.

Authors:  Sarmed S Sami; Krish Ragunath; Prasad G Iyer
Journal:  Clin Gastroenterol Hepatol       Date:  2014-06-02       Impact factor: 11.382

9.  Risk of esophageal adenocarcinoma decreases with height, based on consortium analysis and confirmed by Mendelian randomization.

Authors:  Aaron P Thrift; Harvey A Risch; Lynn Onstad; Nicholas J Shaheen; Alan G Casson; Leslie Bernstein; Douglas A Corley; David M Levine; Wong-Ho Chow; Brian J Reid; Yvonne Romero; Laura J Hardie; Geoffrey Liu; Anna H Wu; Nigel C Bird; Marilie D Gammon; Weimin Ye; David C Whiteman; Thomas L Vaughan
Journal:  Clin Gastroenterol Hepatol       Date:  2014-02-12       Impact factor: 11.382

10.  Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma.

Authors:  Tariq A Hammad; Aaron P Thrift; Hashem B El-Serag; Nisreen S Husain
Journal:  Dig Dis Sci       Date:  2018-10-28       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.